Teleflex Completes Biotronik Vascular Intervention Business Acquisition

July 1, 2025—Teleflex Incorporated announced that it has completed the acquisition of substantially all of the Vascular Intervention business of Biotronik.

On February 27, 2025, Teleflex announced it had entered into a definitive agreement for the transaction. Under the terms of the agreement, Teleflex acquired the Vascular Intervention business for a cash payment of €760 million, less certain adjustments.

According to Teleflex, the acquisition adds a broad portfolio of therapeutic products to its portfolio of interventional access products, establish a global footprint in the peripheral intervention market, and provide a channel for Teleflex products that currently have a peripheral indication.

Teleflex stated that the acquired Vascular Intervention business consists of a portfolio for peripheral and coronary interventions performed in the catheterization lab and interventional radiology suites:

• For peripheral interventions, the portfolio includes the Passeo-18 Lux peripheral drug-coated balloon catheter; the Dynetic-35 balloon-expandable cobalt chromium stent; the Pulsar-18 T3 self-expanding 4-F stent; and the Oscar peripheral multifunctional catheter system.
• For coronary vascular interventions, key products include the Pantera Lux drug-coated balloon catheter; the PK Papyrus covered coronary stent for acute coronary artery perforations; and the ultrathin Orsiro Mission drug-eluting stent.

Additionally, the company stated that the acquisition will allow Teleflex to invest in and expand the clinical trial program for the Freesolve sirolimus-eluting resorbable metallic scaffold (RMS) technology.

Teleflex advised that it plans to initiate the United States pivotal study for the Freesolve RMS, which received CE Mark approval in February 2024. The device is indicated for de novo coronary artery lesions in countries that accept the CE Mark. Enrollment in the BIOMAG-II study is ongoing, noted Teleflex.